A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.


Cag Y. , Icten S., Isik-Goren B., Baysal N., Bektas B., Selvi E., ...More

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, vol.40, pp.407-411, 2021 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40
  • Publication Date: 2021
  • Doi Number: 10.1007/s10096-020-04016-1
  • Title of Journal : European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • Page Numbers: pp.407-411
  • Keywords: Doxycycline, Favipiravir, Lopinavir, Hydroxychloroquine, COVID-19, SUPPRESSOR

Abstract

This manuscript aims to present a treatment algorithm we applied to manage COVID-19 patients admitted to our hospital. During the study period, 2043 patients with suspected COVID-19 were admitted to the emergency department. Molecular tests indicated that 475 of these patients tested positive for COVID-19. We administered hydroxychloroquine plus doxycycline to mild cases (isolated at home) for 3 days and lopinavir plus doxycycline to moderate and severe cases (hospitalized) for 5 days. The overall case fatality rate was 4.2% (20/475).